Burning Rock Biotech (BNR) Accumulated Expenses (2019 - 2025)

Burning Rock Biotech's Accumulated Expenses history runs 7 years deep, the most recent figure standing at $11.4 million for Q4 2025.

• In Q4 2025, Accumulated Expenses fell 8.5% year-over-year to $11.4 million; the TTM figure through Dec 2025 stood at $11.4 million (down 8.5% YoY), while the FY2025 annual figure was $11.6 million, down 5.7% from the prior year.
• Accumulated Expenses was $11.4 million for Q4 2025 at Burning Rock Biotech, down from $12.5 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $24.4 million in Q4 2022 to a low of $11.4 million in Q4 2025.
• Historically, Accumulated Expenses has averaged $16.6 million across 5 years, with a median of $14.6 million in 2023.
• The sharpest annual moves came in 2021 and 2023: Accumulated Expenses surged 58.48% in 2021, then slumped 40.37% in 2023.
• A 5-year view of Accumulated Expenses shows it stood at $20.0 million in 2021, then advanced by 22.19% to $24.4 million in 2022, then slumped by 40.37% to $14.6 million in 2023, then slipped by 14.51% to $12.5 million in 2024, then declined by 8.5% to $11.4 million in 2025.
• The last three Accumulated Expenses figures came in at $11.4 million (Q4 2025), $12.5 million (Q4 2024), and $14.6 million (Q4 2023), per Business Quant data.